Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | ASCO GI: updates in CCA, ALLIANCE & FGFR inhibition

Namrata Vijayvergia • 20 Jan 2021
ASCO GI 2021
Bile Duct Cancer Gastric Cancer Gastrointestinal Cancer Pancreatic Cancer Ivosidenib Pembrolizumab
Alliance A021501

Namrata Vijayvergia, MD, Fox Chase Cancer Center, Philadelphia, PA, talks on some key updates presented at the American Society of Clinical Oncology (ASCO) GI 2021 Virtual Meeting, including updates in IDH1 inhibition in patients with cholangiocarcinoma, as well as the ALLIANCE trial results in pancreatic cancer, where chemotherapy alone demonstrated improved overall survival. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Namrata Vijayvergia

1:45
Computerized food frequency questionnaire to assess dietary patterns in advanced GI cancers
Namrata Vijayvergia • 18 Jan 2021
2:48
Total neoadjuvant therapy + pembrolizumab in locally-advanced rectal cancer
Namrata Vijayvergia • 20 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals